

7:30 am Breakfast	
8:00-8:10 SARC Clinical & Science Initiatives	
Upcoming events & collaborative opportunities	Chappie Conrad MD (SARC Board Chair; UT Houston) Scott Okuno MD (SARC CMO; Mayo Clinic) Steven Young (SARC President & CEO)
8:10-9:50 Targeting DDR and Genomic Integrity in Sarcoma	
Introductions by Moderators	Jonathan Fletcher MD (SARC CSO; Harvard Med School) Rebecca Gladly MD PhD (U. of Toronto)
Manipulating DDR protein localization: Tx strategies	David Loeb MD PhD (Albert Einstein College of Medicine)
Precision oncology in osteosarcoma	Katie Janeway MD (Dana-Farber Cancer Institute)
PARPi: combination therapy strategies	Geoffrey Shapiro MD PhD (Dana-Farber Cancer Inst.)
RT + immunotherapy insights relevant for future clinical trials	David Kirsch MD PhD (Princess Margaret Cancer Centre, UHN)
Discussion	
9:50-10:20 Break (30 minutes)	
10:20-11:20 SARC028: Lessons Learned/Paths Forward	
Introductions	Scott Okuno MD
Moderator/Coordinator	Sandra D'Angelo MD (Memorial Sloan Kettering Cancer Center)
SARC 028: Development and Results	Melissa "Missy" Burgess MD (U. of Pittsburgh Medical Center)
TLS as a Predictor biomarker	Proponents: Emily Z. Keung MD (MD Anderson Cancer Center) & Florent Petitprez PhD (U. of Edinburgh) Against: Breelyn Wilky MD (U. of Colorado)
Discussion	
11:20-11:45 Career Awardee Presentation	
Androgen receptor targeting in DSRCT	Danh Truong PhD (MD Anderson Cancer Center)
11:45-12:00 SARC-Sponsored Clinical Trials	
Introductions	Presenter (bolded) Scott Okuno MD
SARC037 Phase I/II Trabectedin in Ewing Sarcoma in Combination with Irinotecan & 18F-FLT Imaging	Patrick Grohar MD PhD (Children's Hospital of Philadelphia): PI Rashmi Chugh MD (U. of Michigan): Co-I
SARC041 Phase III Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS	Mark Dickson MD (Memorial Sloan Kettering Cancer Center): PI Bill Tap MD (MSKCC): Temporary PI
SARC044 Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST who Progressed on Sunitinib Monotherapy	Candace Haddox MD (Dana-Farber Cancer Institute): PI
12:00 noon Closing Comments & Adjourn	

THANK YOU TO OUR PLATINUM SPONSOR

Additional Funding Provided by

